Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;4(1):e2-e3.
doi: 10.1016/S2665-9913(21)00353-2. Epub 2021 Nov 17.

Who, what, and when-effective therapy for severe COVID-19

Daniel A Kelmenson  1 , Randy Q Cron  2
Affiliations

Who, what, and when-effective therapy for severe COVID-19

Daniel A Kelmenson et al. Lancet Rheumatol. 2022 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

RQC reports grants and personal fees from Sobi, personal fees from Novartis, personal fees from Pfizer during the conduct of the study. DAK declares no competing interests.

References

    1. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72:1059–1063. - PMC - PubMed
    1. Group RECOVERY. Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020 - PubMed
    1. Cron RQ, Schulert GS, Tattersall RS. Defining the scourge of COVID-19 hyperinflammatory syndrome. Lancet Rheumatol. 2020;2:e727–e729. - PMC - PubMed
    1. Group WHO-REACT. Shankar-Hari M, Vale CL, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518. - PMC - PubMed
    1. The CORIMUNO-19 Collaborative group Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia. An open-label randomised controlled trial. Lancet Rheumatol. 2021 doi: 10.1016/S2665-9913(21)00315-5. published online Nov 17. - DOI - PMC - PubMed

LinkOut - more resources